Evidence map›Paper›PMID 42866117›Full record

ReviewMaterials today. Bio2026

Activatable MRI nanoprobes for tumor and immune microenvironment imaging: biological mechanisms and translational implications.

Kexin Wang, Zhihao Wei, Xinyang Lu, Sen Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kexin WangMedical Imaging Department, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, 272007, China.
Zhihao WeiGuangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, 510095, China.
Xinyang LuDepartment of Gastrointestinal Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, 272007, China.
Sen WangDepartment of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272007, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although magnetic resonance imaging (MRI) remains indispensable in oncology, conventional contrast agents lack the biological specificity required to resolve cellular-level pathological events. This review critically examines pivotal advances (2023-2026) in activatable biomaterial-based MRI nanoprobes for precision theranostics. These intelligent platforms convert tumor-associated biological cues into high-fidelity imaging signals while simultaneously enabling targeted therapeutic interventions. We dissect key structural and compositional innovations, spanning high-relaxivity metal-chelating assemblies, zero-background

Indexed as

19FActivatable MRI nanoprobesImmunotherapy monitoringMachine learningPrecision theranosticsTumor microenvironment

Identifiers

PMID42866117
PMCPMC13656969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.